FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2110941212> ?p ?o ?g. }

• W2110941212 endingPage "3938" @default.
• W2110941212 startingPage "3932" @default.
• W2110941212 abstract "There is increasing recognition of the existence of intratumoral heterogeneity of the human epidermal growth factor receptor (HER2), which affects interpretation of HER2 positivity in clinical practice and may have implications for patient prognosis and treatment. We determined the frequency and prognostic impact of heterogeneous HER2 gene amplification and polysomy 17 in patients with esophageal adenocarcinoma (EAC).HER2 amplification (by fluorescence in situ hybridization) was examined in surgical EAC specimens (n = 675). HER2 heterogeneity was defined according to consensus guidelines as gene amplification (HER2/CEP17 ratio ≥ 2.0) in more than 5% but less than 50% of cancer cells. No patient received neoadjuvant or HER2-targeted therapy. Cox models were used to assess disease-specific survival (DSS) and overall survival (OS).Overall, 117 EACs (17%) demonstrated HER2 amplification, of which 20 (17%) showed HER2 heterogeneity. All HER2-heterogeneous tumors were amplified. Among HER2-amplified tumors, heterogeneous tumors had significantly higher frequency of poor histologic grade and polysomy 17. In multivariable models that included number of metastatic lymph nodes, grade, tumor stage, and polysomy 17, only HER2 heterogeneity and node number were prognostic among HER2-amplified tumors, with heterogeneity showing worse DSS (hazard ratio, 2.04; 95% CI, 1.09 to 3.79; P = .025) and OS (P = .026). Among HER2-nonamplified EACs, polysomy 17 was independently associated with worse DSS (P = .012) and OS (P = .023).Among HER2-amplified EACs, 17% show HER2 heterogeneity, which independently predicts for worse cancer-specific death. Among HER2-nonamplified EACs, polysomy 17 is independently associated with worse survival. These novel findings demonstrate aggressive subgroups in HER2-amplified and -nonamplified EACs that have important implications for HER2 analysis and determination of benefit from HER2-targeted therapy." @default.
• W2110941212 created "2016-06-24" @default.
• W2110941212 creator A5002209179 @default.
• W2110941212 creator A5013749695 @default.
• W2110941212 creator A5035911030 @default.
• W2110941212 creator A5045186065 @default.
• W2110941212 creator A5049291606 @default.
• W2110941212 creator A5060720802 @default.
• W2110941212 creator A5064038800 @default.
• W2110941212 creator A5069073626 @default.
• W2110941212 creator A5070740990 @default.
• W2110941212 creator A5075740509 @default.
• W2110941212 date "2012-11-10" @default.
• W2110941212 modified "2023-10-17" @default.
• W2110941212 title "Adverse Prognostic Impact of Intratumor Heterogeneous <i>HER2</i> Gene Amplification in Patients With Esophageal Adenocarcinoma" @default.
• W2110941212 cites W1486586988 @default.
• W2110941212 cites W1945181719 @default.
• W2110941212 cites W1968041240 @default.
• W2110941212 cites W1978496694 @default.
• W2110941212 cites W1987009448 @default.
• W2110941212 cites W1998758456 @default.
• W2110941212 cites W2007371434 @default.
• W2110941212 cites W2014312052 @default.
• W2110941212 cites W2018572593 @default.
• W2110941212 cites W2040708197 @default.
• W2110941212 cites W2042095374 @default.
• W2110941212 cites W2045443563 @default.
• W2110941212 cites W2045733317 @default.
• W2110941212 cites W2045829974 @default.
• W2110941212 cites W2048982865 @default.
• W2110941212 cites W2060084956 @default.
• W2110941212 cites W2062004184 @default.
• W2110941212 cites W2067708830 @default.
• W2110941212 cites W2072336754 @default.
• W2110941212 cites W2075657881 @default.
• W2110941212 cites W2078399076 @default.
• W2110941212 cites W2091448280 @default.
• W2110941212 cites W2095156669 @default.
• W2110941212 cites W2099630695 @default.
• W2110941212 cites W2100439220 @default.
• W2110941212 cites W2102626211 @default.
• W2110941212 cites W2103908350 @default.
• W2110941212 cites W2103939496 @default.
• W2110941212 cites W2104159606 @default.
• W2110941212 cites W2104558660 @default.
• W2110941212 cites W2109194250 @default.
• W2110941212 cites W2110577005 @default.
• W2110941212 cites W2111253826 @default.
• W2110941212 cites W2119046955 @default.
• W2110941212 cites W2122380766 @default.
• W2110941212 cites W2125157023 @default.
• W2110941212 cites W2130900820 @default.
• W2110941212 cites W2131738928 @default.
• W2110941212 cites W2135990563 @default.
• W2110941212 cites W2144891384 @default.
• W2110941212 cites W2148930326 @default.
• W2110941212 cites W2157719382 @default.
• W2110941212 cites W2158734599 @default.
• W2110941212 cites W2163859522 @default.
• W2110941212 cites W3020879346 @default.
• W2110941212 cites W4252560545 @default.
• W2110941212 cites W4253149507 @default.
• W2110941212 doi "https://doi.org/10.1200/jco.2012.43.1890" @default.
• W2110941212 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3675687" @default.
• W2110941212 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22987085" @default.
• W2110941212 hasPublicationYear "2012" @default.
• W2110941212 type Work @default.
• W2110941212 sameAs 2110941212 @default.
• W2110941212 citedByCount "80" @default.
• W2110941212 countsByYear W21109412122013 @default.
• W2110941212 countsByYear W21109412122014 @default.
• W2110941212 countsByYear W21109412122015 @default.
• W2110941212 countsByYear W21109412122016 @default.
• W2110941212 countsByYear W21109412122017 @default.
• W2110941212 countsByYear W21109412122018 @default.
• W2110941212 countsByYear W21109412122019 @default.
• W2110941212 countsByYear W21109412122020 @default.
• W2110941212 countsByYear W21109412122021 @default.
• W2110941212 countsByYear W21109412122022 @default.
• W2110941212 countsByYear W21109412122023 @default.
• W2110941212 crossrefType "journal-article" @default.
• W2110941212 hasAuthorship W2110941212A5002209179 @default.
• W2110941212 hasAuthorship W2110941212A5013749695 @default.
• W2110941212 hasAuthorship W2110941212A5035911030 @default.
• W2110941212 hasAuthorship W2110941212A5045186065 @default.
• W2110941212 hasAuthorship W2110941212A5049291606 @default.
• W2110941212 hasAuthorship W2110941212A5060720802 @default.
• W2110941212 hasAuthorship W2110941212A5064038800 @default.
• W2110941212 hasAuthorship W2110941212A5069073626 @default.
• W2110941212 hasAuthorship W2110941212A5070740990 @default.
• W2110941212 hasAuthorship W2110941212A5075740509 @default.
• W2110941212 hasBestOaLocation W21109412121 @default.
• W2110941212 hasConcept C104317684 @default.
• W2110941212 hasConcept C120821319 @default.
• W2110941212 hasConcept C121608353 @default.
• W2110941212 hasConcept C126322002 @default.
• W2110941212 hasConcept C141231307 @default.
• W2110941212 hasConcept C142724271 @default.

• next